Education
About Us
Working with TipRanks
Follow Us
Merck & Company (DE:6MK)
:6MK
Earnings Data
Report Date
Jul 29, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.84Last Year’s EPS
2.04Same Quarter Last Year
Moderate Buy
Based on 17 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 24, 2025
|% Change Since: -3.90%
|Next Earnings Date:Jul 29, 2025
Earnings Call Sentiment|Neutral
The call presented a balanced view with strong emphasis on future growth potential through a robust pipeline and key product launches, while addressing challenges such as declining Gardasil sales in China and the impact of tariffs and foreign exchange. While there are significant growth drivers, the lowlights indicate notable challenges that could affect near-term performance.Company Guidance
During the Merck & Co., Inc. Q1 2025 earnings call, the company reported revenues of $15.5 billion, reflecting a 1% increase excluding foreign exchange impacts. Oncology sales, driven by Keytruda, grew by 6% to $7.2 billion, while new products like WinRevair and Capfaxiv also contributed positively. Gardasil sales decreased by 40% due to reduced demand in China, but global growth excluding China was 8%. The company maintained its 2025 revenue guidance of $64.1 to $65.6 billion, with expected EPS of $8.82 to $8.97. Merck highlighted a strong pipeline with over 20 potential blockbuster products and investments in US manufacturing totaling more than $21 billion since 2018. The call also addressed tariff impacts, with $200 million in costs anticipated, and emphasized ongoing efforts to optimize the supply chain.Strong Pipeline and Future Growth Potential
Merck highlighted a robust pipeline with over 20 new products expected to launch in the next few years, most of which have blockbuster potential, contributing to a potential commercial opportunity of over $50 billion by the mid-2030s.
Key Product Launches and Growth Drivers
Significant contributions from new products WinRevair and Capfaxiv, with WinRevair achieving global sales of $280 million and robust uptake in the treatment of pulmonary arterial hypertension.
Oncology Segment Performance
Keytruda sales grew by 6% to $7.2 billion with strong demand in both early-stage and metastatic cancers. Welireg sales increased 63% to $137 million, leading in the treatment of advanced renal cell carcinoma.
Animal Health Business Growth
The animal health segment delivered a strong performance with sales increasing by 10% due to higher demand across all species and recent acquisitions.
---
DE:6MK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DE:6MK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 24, 2025 | €69.30 | €68.90 | -0.58% |
Feb 04, 2025 | €95.27 | €84.96 | -10.82% |
Oct 31, 2024 | €94.02 | €92.54 | -1.57% |
Jul 30, 2024 | €114.89 | €104.73 | -8.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Merck & Company (DE:6MK) report earnings?
Merck & Company (DE:6MK) is schdueled to report earning on Jul 29, 2025, TBA Not Confirmed.
What is Merck & Company (DE:6MK) earnings time?
Merck & Company (DE:6MK) earnings time is at Jul 29, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Merck & Company stock?
The P/E ratio of Merck & Company is N/A.
What is DE:6MK EPS forecast?
DE:6MK EPS forecast for the fiscal quarter 2025 (Q2) is 1.84.
---
